
- ONCOLOGY Vol 40, Issue 8
- Volume 40
- Issue 8
- Pages: 247-250
Gedatolisib Joins a Biomarker-Driven Second-Line Algorithm in HR+/HER2– mBC
In this program recap, a panel of experts discussed second-line treatment of hormone receptor–positive, HER2-negative metastatic breast cancer.
In this CancerNetwork Around the Practice program, moderator Seth Wander, MD, PhD, director of translational research for the breast cancer program at Massachusetts General Hospital, discussed second-line treatment of hormone receptor–positive, HER2-negative metastatic breast cancer (mBC). He was joined on the panel by Erica Mayer, MD, MPH, director of breast cancer clinical research, institute physician at Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School; Kathryn Post, PhD, RN, ANP-BC, a nurse practitioner at Mass General Brigham Cancer Institute, and nurse scientist, Cancer Outcomes Research & Education (CORE) Program; and Jennifer Hutchinson, PharmD, BCOP, an oncology clinical pharmacy specialist for breast cancer at Massachusetts General Hospital.
The panel covered biomarker testing at first progression, oral selective estrogen receptor degraders (SERDs) for ESR1-mutant disease, capivasertib (Truqap) and alpelisib (Piqray) for PI3K pathway alterations, emerging doublets from the phase 3 trials of EMBER-3 (NCT04975308), evERA (NCT05306340), and SERENA-6 (NCT04964934), and the VIKTORIA-1 (NCT05501886) data behind the recent FDA approval of gedatolisib (Revtorpyk) for PIK3CA wild-type disease.1-3 Alongside the efficacy signals, the panelists addressed open questions: a fulvestrant monotherapy control arm, a mucositis rate near 60% despite mandatory steroid mouthwash, the commitment to a weekly intravenous (IV) schedule, and the absence of sequencing data for novel endocrine agents given after one another.
[Editor’s Note: This program was filmed prior to the FDA’s approvals of camizestrant on September 4, 2026, and imlunestrant on September 18, 2026.]
Biomarker Testing at First Progression
Q / Wander: How do you frame the second-line discussion for a patient who has progressed on a CDK4/6 inhibitor with an aromatase inhibitor, and what testing do you complete before choosing the next agent?
Mayer / We are primarily looking for actionable mutations; the most key are PI3K pathway mutations and/or ESR1 mutations. If I think a patient is progressing into second line, I want to check again, because ESR1 mutations are kinetic. They’re rarely seen at the time of first diagnosis of metastatic disease, but they develop during first-line therapy on an aromatase inhibitor. Sending a blood-based test for [circulating tumor DNA (ctDNA)] would be my preferred approach, and it is supported by global guidelines.
The Second-Line Algorithm
Q / Wander: Give us a 50,000-foot view of the second-line setting as of today, knowing this is changing every couple of weeks or months.
Mayer / If an ESR1 mutation has developed, that’s when I would want to bring in an oral SERD or a novel ER [estrogen receptor]–targeting agent. If we have a PI3K pathway mutation and we have not already addressed that pathway, this would be the time to do it. We have alpelisib historically available; honestly, it’s not something many of us use, given the toxicity profile. Many of us would offer capivasertib in that setting. Then we have the category of patients who do not have an actionable mutation. Options there include switching to abemaciclib [Verzenio] or ribociclib [Kisqali], everolimus [Afinitor], based on the classic BOLERO-2 study [NCT00863655], and one of our newest options, gedatolisib in combination with fulvestrant, plus or minus palbociclib [Ibrance]. Gedatolisib is a PAM [PI3K/AKT/mTOR] pathway inhibitor that has activity in both the wild-type and the mutant settings.
Where Gedatolisib Fits
Q / Wander: The biomarker-negative population is an area of unmet clinical need. How often are you seeing it, and how are you framing that conversation in the current era?
Mayer / We know about 40% of people will develop an ESR1 mutation, and approximately 40% will have a PAM pathway mutation. There is overlap, so that leaves the rest without an actionable mutation. A patient with a very long duration on a prior CDK4/6 inhibitor may be a person for whom continuing another CDK4/6 inhibitor makes sense. Everolimus is still quite active with the right prophylaxis. We’re all excited about the new gedatolisib option. This regimen has shown favorable PFS [progression-free survival] and response rate data in patients who had a prior CDK4/6 inhibitor. Particularly if I have a patient where I’m concerned about the pace or volume of disease, and I want that response rate, that’s a situation where it would be a top-of-the-list option.
PI3K Pathway–Mutant Disease: Alpelisib and Capivasertib
Q / Wander: Alpelisib, capivasertib, and everolimus each have a distinct patient population and toxicity profile. How are you deciding among those in the mutant population?
Mayer / My treatment of preference in that setting would be capivasertib. When alpelisib was approved, many of us found it tricky to use, particularly with hyperglycemia. When capivasertib came, with lower rates of hyperglycemia and toxicities like diarrhea and rash that feel easier to control, that became a preferred strategy. The thing we’re waiting for will be the second approval of gedatolisib for PAM pathway mutations, based on the VIKTORIA-1 trial presented at the American Society of Clinical Oncology [ASCO] earlier this year, which showed striking progression-free survival benefits for both the triplet and the doublet in comparison with an alpelisib-based regimen, and a response rate of 50% in the triplet, which you don’t see much in endocrine- based regimens.
Hutchinson / In the phase 3 SOLAR-1 trial [NCT02437318], the risk of hyperglycemia with alpelisib was upwards of 60% of patients. When we’re considering whether to start a patient on alpelisib, the major thing to consider is their metabolic risk factors: a history of uncontrolled type 2 diabetes or type 1 diabetes, or [hemoglobin] A1c [HbA1c] over 6.5%. The benefit of capivasertib is that we are seeing much lower rates of hyperglycemia; in the CAPItello-291 trial [NCT04305496], that was around 16%. The offset is higher rates of diarrhea and rash, and oftentimes, that is happening sooner, within the first 1 to 2 weeks after initiation.
Post / Our practice has shifted. We jumped right in with alpelisib, but due to its toxicity, we have moved away from that. We’re treating many more patients with a capivasertib-based regimen now, with much less hyperglycemia than alpelisib and much less stomatitis
than everolimus.
ESR1-Mutant Disease and the Oral SERD Class
Q / Wander: For a patient who has progressed on an AI [aromatase inhibitor] and a CDK4/6 inhibitor and now has a single ESR1 alteration, what’s available, and what are you choosing in practice?
Mayer / We’ve seen data with 3 agents as monotherapy, elacestrant [Orserdu], imlunestrant [Inluriyo], and vepdegestrant [Veppanu], which is a PROTAC [proteolysis targeting chimera] as opposed to an oral SERD, that have demonstrated superior progression-free survival vs standard endocrine therapy in ESR1-mutant disease. We are also beginning to have access to the first doublet, imlunestrant and abemaciclib, based on EMBER-3, listed in [National Comprehensive Cancer Network] guidelines, although not yet FDA approved. We also have emerging evERA data with giredestrant and everolimus, and we hope to see approval later this year. In general, my preference would be to use combinations in the post-CDK4/6 setting, since a combination of an oral SERD with a targeted partner consistently gives progression-free survival well above 6 months. However, for patients with slower-growing, bone-only disease, or who are older or frail, monotherapy can be a terrific option.
Emerging Doublets and SERENA-6
Q / Wander: We have 3 trials that could enable labels for next-generation antiestrogen doublets: EMBER-3, evERA, and SERENA-6. Are you going to test on treatment for ESR1 and go the SERENA-6 route, or wait for clinical progression and deploy a doublet?
Mayer / The wild card is SERENA-6, an innovative trial in what we might think of as the 1.5-line setting. Patients on a first-line aromatase inhibitor and CDK4/6 inhibitor had serial ctDNA screening, and if an ESR1 mutation emerged without clinical progression, they were [randomly assigned] to switch to camizestrant with the same CDK4/6 inhibitor or remain on their regimen. Those who switched had a significant improvement in progression- free survival, 9 months to 16 months, and a substantial delay in quality-of-life deterioration. If that becomes an approved approach, we would be thinking about testing earlier and serially. Eventually, that cancer will progress. We don’t yet have data for oral SERD after oral SERD, or a PROTAC after an oral SERD, so I would be somewhat unsure about going in that direction, but I certainly want to study it and learn more.
VIKTORIA-1: Trial Design, Gedatolisib Efficacy, and Toxicity
Q / Wander: VIKTORIA-1 is for sure a practice-changing study. We now have an FDA approval for gedatolisib as a doublet and a triplet in the PIK3CA wild-type population. Tell us about the design and key outcomes.
Mayer / VIKTORIA-1 has 6 arms, so it’s good to break it into study 1 and study 2. All patients had a prior CDK4/6 inhibitor, up to 2 prior lines of endocrine therapy, and no prior chemotherapy. There was an [HbA1c] restriction of 6.4% and no type 1 diabetes, similar to the alpelisib trial. In the wild-type population, patients were [randomly assigned] 1:1:1 to the triplet of gedatolisib, fulvestrant, and palbociclib, so CDK4/6 after CDK4/6; a doublet of gedatolisib and fulvestrant; or fulvestrant monotherapy, a treatment strategy that, in all honesty, we don’t use much anymore. PFS was about 9 months for the triplet and about 7 months for the doublet, compared with 2 months for the monotherapy. The response rate in both gedatolisib arms was about 30%, which we don’t often see for endocrine-based strategies. The key toxicity here is mucositis, and about 60% of patients had all-grade mucositis, despite mandatory use of steroid mouthwash, which was perhaps a little higher than expected. The rates of diarrhea, rash, and, importantly, hyperglycemia were lower than with some of the other agents. One final thing to note: This is an [IV] therapy, a quick IV infusion, 3 weeks on, 1 week off. Patients and providers have feelings on both ends of the spectrum as to whether that is good or bad.
Study 2, presented at ASCO this year, enrolled patients with PAM pathway mutations, [randomly assigned] 3:3:1 to the triplet, the doublet, or alpelisib and fulvestrant, a little more of a modern control arm. Both gedatolisib arms performed well, with PFS of more than 11 months. The response rate in the triplet arm was about 50%.
Pan-PI3K/mTOR Biology and the Intravenous Trade-Off
Q / Wander: Jennifer, tell us about the biology of this drug, what targets it’s hitting within the pathway, and how that relates to the toxicity profile.
Hutchinson / The novel thing about gedatolisib is that it enacts a vertical blockade of the entire PAM pathway. It targets all 4 class I isoforms of PI3K along with both complexes of mTOR. We’re seeing the conventional PI3K inhibitor toxicities, like hyperglycemia, rash, and diarrhea, but we’re
also pulling in the mTOR inhibitor toxicities, specifically stomatitis. It’s a broader range, but manageable compared with some single-node agents, especially alpelisib.
Wander / When we look at the toxicity rates across SOLAR-1, CAPItello-291, and the phase 3 INAVO120 trial [NCT04191499], and VIKTORIA-1, gedatolisib has the lowest rates of hyperglycemia, despite broader pathway inhibition. This is the trade-off with the IV route. Earlier PI3K/mTOR dual blockers were all too toxic; it’s this IV formulation that has radically changed our ability to comprehensively hit that pathway.
Hutchinson / It’s important that we’re emphasizing this isn’t an oral therapy. There is a commitment to weekly infusions, but the trade-off is fewer of these toxicities. It’s also important to emphasize that this isn’t chemotherapy; you’re not seeing those conventional toxicities.
Post / Even if they’re not diabetic, they may be on that verge, and time toxicity with the IV formulation matters for some. Although this regimen seems to be well tolerated, these patients are coming from a regimen that probably has less toxicity, so this is still a switch for them. It’s about up-front education about red flags vs things they can self-manage at home.
The most important thing when we speak to toxicity is giving them a plan, so that they feel empowered and able to deal with whatever might come up, and letting them know that we are always available if they have questions at home, so that we can help them stay on these therapies.
Managing Hyperglycemia and Stomatitis
Q / Wander: Katie and I are going to call you and say we’re writing a prescription for gedatolisib. What’s our baseline workup, what’s the monitoring frequency, and when do we engage endocrinology? What’s the day 1 plan for stomatitis?
Hutchinson / We use home glucometers or local labs. For patients verging up to that 6.5% [HbA1c], we might do even more frequent monitoring than what’s recommended in the package insert, and we make sure the patient is aware to contact our clinic if their blood glucose is above 160 [mg/dL]. Our clinic is comfortable starting metformin, but beyond that, we loop in endocrinology or their [primary care physician] early on.
Hutchinson / Dexamethasone mouth rinses starting on day 1, plus a salt-and-soda swish several times a day, avoiding alcohol-based rinses, and good oral hygiene. If they develop stomatitis, we can pause the drug and decrease the dose.
Visit Frequency and Caregivers
Q / Wander: With some once-daily oral agents, patients can go a month or more between visits. As an advanced practice provider (APP), how do more frequent in-person or virtual visits impact detecting adverse events, adherence, and treatment goals?
Post / We like to see patients more frequently as they start a new regimen, so that we are reinforcing education and talking about toxicities, and this is often required by the label. Virtual visits are key when we can have patients do this from home, and local labs let us keep close contact while decreasing burden.
Caregivers are a second set of eyes at home. A patient may want to present their best face to us in clinic, but the caregiver might say, “You didn’t get out of bed” or “The diarrhea was a little worse than what you’re describing.” That way, we can help them better self-manage so that they can stay on therapy. Most importantly, caregivers are a source of emotional support.
Antibody-Drug Conjugates and the Leap From Endocrine Therapy
Q / Wander: We’ve had multiple new antibody-drug conjugate [ADC] approvals for refractory ER-positive metastatic breast cancer. When do those enter the conversation for you, and what’s your first choice there?
Mayer / I tend to think of ADCs as fancy chemotherapy, much more precisely delivered, with much greater efficacy. In the second line and beyond, we have fam-trastuzumab deruxtecan-nxki [Enhertu], sacituzumab govitecan-hziy [Trodelvy], and our newest one, datopotamab deruxtecan [Datroway]. The gap in the ADC space is sequencing. That leap from the endocrine space to the chemotherapy space is where the art of oncology comes in. Is the cancer still sensitive to endocrine treatments? Is there organ involvement where we need the response? Is the patient ready to make that jump? Many of our patients dread that moment, so putting it off as long as possible has been a big goal. That’s why it’s so gratifying to see endocrine-based trials showing improvements in time to chemotherapy; that’s one of the most meaningful data points for our patients.
Changing Routes of Administration and Starting Treatment as a Team
Q / Wander: Katie, when a patient moves from an oral regimen to a different route of administration, how are you framing that conversation around efficacy, safety, schedule, and convenience?
Post / It can be such a difficult transition for patients with hormone receptor–
positive advanced breast cancer who may have been on oral regimens for years. One of the most important things we try to do is set the stage for these decision points. Every time we have to make a change in therapy, we talk about what we will do next if this doesn’t go well in terms of efficacy or tolerability, so that it isn’t a surprise. It’s also so much more patient- centered, because we can talk about goals of care and how switching from oral to IV therapy will impact their life.
Hutchinson / Everyone comes to see me for a new teaching, about an hour long, sitting down with the patient and their caregivers and going through not just the treatment plan but the [adverse] effects and what our plan is if something were to happen. By equipping patients with that knowledge, they feel more adherent and more accepting of the treatment plan. Our nurses triage questions, oncologists and APPs follow along, and pharmacy is involved for unusual toxicity.
Post / Most of the patients we are recommending these regimens for are really motivated to be adherent, so the primary barrier I see is toxicity. I always frame it with patients like this: I’m going to share what we typically see on these medications, but you are an individual, so we’re going to learn together and adapt. I also always let patients know that quality of life is absolutely a priority for us. We do not expect them to live with debilitating adverse effects.
References
1. Bidard FC, Mayer EL, Park YH, et al. First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer: final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial. J Clin Oncol. 2026;44(suppl 17):LBA1007. doi:10.1200/JCO.2026.44.17_suppl.LBA1007
2. Hurvitz SA, Layman RM, Curigliano G, et al. Gedatolisib plus fulvestrant, with & without palbociclib, vs fulvestrant in patients with HR+/HER2-/PIK3CA wild-type advanced breast cancer: first results from VIKTORIA-1. Presented at: ESMO Congress 2025; October 17-21, 2025; Berlin, Germany. Abstract LBA17.
3. FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer. FDA. July 14, 2026. Accessed September 15, 2026. https://tinyurl.com/yck3eabf
Articles in this issue
about 1 hour ago
3 Patient Profiles: ADC Therapy in TNBCabout 1 hour ago
3 Things You Should Know About MET-Altered NSCLCRelated to this article




